Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil

Journal of Medical Economics

Volumn 11, Issue 2, 2008, Pages 311-325

  Caponero, Ricardo ^a   de Albuquerque Ribeiro, Ronaldo ^b   Santos, Eduardo ^c   Cirrincione, Alessandro ^d   Saggia, Mario ^c  

^a HOSPITAL BRIGADEIRO   (Brazil)

^b Instituto do Cancer do Ceara   (Brazil)

^c Roche Pharmaceuticals SA   (Brazil)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Capecitabine; Catheterisation; Central venous; Colorectal neoplasms; Delphi technique; Pharmacoeconomics

Indexed keywords

CAPECITABINE; ERYTHROPOIETIN; FERROUS SULFATE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GLUCONATE CALCIUM; IRINOTECAN; MAGNESIUM SULFATE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; BRAZIL; COLORECTAL CANCER; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DELPHI STUDY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; NEUTROPENIA;

ANTINEOPLASTIC AGENTS; BRAZIL; COLORECTAL NEOPLASMS; CONSENSUS; DELPHI TECHNIQUE; FEMALE; HEALTH SERVICES; HUMANS; MALE; NEOPLASM METASTASIS;

EID: 50649096352     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802160817     Document Type: Article

References (38)

1. Stewart BJ, Kleihues P. World Cancer Report. Lyon; IARC Press, 2003.
2. Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2006: Incidência de Câncer no Brasil. Accessed 5 July 2007 from: http://www.inca.gov.br/estimativa/ 2006/.
3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. Journal of Clinical Oncology 1992; 10: 896-903.
4. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. Journal of Clinical Oncology 1998; 16: 301-308.
5. Saad ED, Hoff PM. Chemotherapy of metastatic colorectal cancer. Current Treatment Options in Gastroenterology 2005; 8: 239-247.
6. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology 2001; 19: 2282-2292.
7. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. Journal of Clinical Oncology 2001; 19: 4097-4106.
8. Saltz LB, Cox JV Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine 2000; 343: 905-914.
9. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2004; 22: 23-30.
10. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004; 350: 2335-2342.
11. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004; 351: 337-345.
12. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007; 25: 1658-1664.
13. Kelly C, Cassidy J. Capecitabine in the treatment of colorectal cancer. Expert Reviews in Anticancer Therapy 2007; 7: 803-810.
14. Terstriep S, Grothey A. First- and second-line therapy of metastatic colorectal cancer. Expert Reviews in Anticancer Therapy 2006; 6: 921-930.
15. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 3510.
16. Cassidy J, Clarke S, Diaz-Rubio E et al. First efficacy and safety results from XELOX-1/NO 16966, a randomized 2x2 factorial Phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (mCRC). Annals of Oncology 2006; 17:(Suppl 9, late breaking abstract 3).
17. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4030.
18. Perrocheau G, Bennouna J, Ducreux M et al. Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (mCRC) in the French setting. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4083.
19. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. New England Journal of Medicine 2004; 351: 317-319.
20. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings. Pharmacoeconomics 1997; 12: 121-129.
21. Murphy MK, Black NA, Lamping DL et al. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment 1998; 2: i-iv 1-88.
22. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 2004; 22: 229-237.
23. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2004; 22: 2084-2091.
24. Bajetta E, Di Bartolomeo M, Mariani L et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-287.
25. Wolmark N, Wieand HS, Kuebler JP et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Journal of Clinical Oncology 2005; 23: 246S(Suppl, late breaking abstract 3500).
26. Guia Farmacêutico Brasíndice, Novembro 2006. São Paulo: Andrei Publicações Médicas, Farmacêuticas e Técnicas Ltda, 2006.
27. Associação Médica Brasileira. Classificação Brasileira Hierarquizada de Procedimentos Médicos-CBHPM. Brasília: AMB-Associação Médica Brasileira, 2004.
28. Revista Simpro, n. 45, 2006.
29. Programa de Estudos Avançados em Administração Hospitalar e de Sistemas de Saúde - PROAHSA. Composição dos custos hospitalares. Indicadores PROAHSA. 41, 2006.
30. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford: Oxford University Press, 2005.
31. Manual Geral de Condutas SBOC (16/11/2007). Available at http://www.sboc.org.br/ [in portuguese].
32. Wiseman LR, Lyseng-Williamson KA. Management of metastatic colorectal cancer: defining the role of capecitabine. Disease Management & Health Outcomes 2005; 13: 137-149.
33. Matasar MJ, Sundararajan V, Grann VR et al. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs & Aging 2004; 21: 113-133.
34. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 1997; 15: 110-115.
35. Jansman FG, Postma MJ, van Hartskamp D et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clinical Therapy 2004; 26: 579-589.
36. Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a Phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer 2001; 37: 597-604.
37. Scheithauer W, Cassidy J, Figer A et al. A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (mCRC): XELOX vs. FOLFOX4 ± bevacizumab (A). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4098.
38. Garrison L, Cassidy J, Saleh M et al. Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4074.